Penwest Pharmaceuticals Co

Penwest Pharmaceuticals — Proxy Contest (June 2010)

43 slides from Penwest Pharmaceuticals's proxy contest presentation, Jun 3, 2010

  1. Slide 1: Focused Business Plan and Execution: Driving Shareholder Value

    NASDAQ: PPCO Focused Business Plan and Execution: Driving Shareholder Value June 2010

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The matters discussed herein contain forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, which may cause the actual results in future periods to be materially

  3. Slide 3: Information Concerning Participants

    Information Concerning Participants Information required to be disclosed with nominees, officers and employees who, under the rules of the Securities and Exchange Commission (the “SEC”), are considered to solicitation of proxies from its shareholders in connection with its 2010 Annual Meeting of Sha

  4. Slide 4: Agenda

    Agenda Overview Jennifer Good, President & CEO Business Plan and Execution Jennifer Good Board Focus on Shareholder Value David Meeker, MD Board Member 2010 Nominating and Governance Committee, Anne VanLent Conclusions Chair, Nominating and Governance Committee Conclusion Jennifer Good 4

  5. Slide 5: Overview

    Overview

  6. Slide 6: Overview of Issues in Proxy Contest

    Overview of Issues in Proxy Contest Penwest at a critical point; needs steady experienced hand Now is not the time for change Current team has been successful implementing its plan Worked cooperatively with Tang and Edelman since their election and seriously considered their viewpoints Focused busin

  7. Slide 7: Penwest Proxy Contest: What a Difference a Year Makes

    Penwest Proxy Contest What a Difference a Year Makes Last year s contest We presented our 2009 focused business plan Explained why we thought we could build shareholder value in short term and long term Wind down did not make sense We were proven right! Achieved our 2009 goals Stock appreciated 102%

  8. Slide 8: 2009/2010 Stock Performance

    2009/2010 Stock Performance Execution of focused Plan has created value for our shareholders $4.00 138% $3.74 $3.50 22% $3.00 $2.92 102% $2.59 $2.50 $2.00 $1.57 $1.50 $1.00 Dec 31, 2008 Dec 31, 2009 April 23, 2010 May 28, 2010 date prior to announcement of proxy contest 8

  9. Slide 9: Business Plan and Execution

    Business Plan and Execution

  10. Slide 10: Penwest 2009 Key Milestones

    Penwest 2009 Key Milestones Strong Execution! Opana ® ER Increasing sales by our partner Endo X Additional issued patents Signed ex-U.S. marketing collaboration A0001 Completed Phase Ib multiple ascending dose safety study in healthy volunteers with data by end of Q2 09 Conducted six month preclinic

  11. Slide 11: Highlights of Progress Over Past Year

    Penwest Highlights of Progress Over Past Year Posted 3 consecutive quarters of Guided for full year profitability in 2010 Continued maximizing the value of Opana ® ER with Endo Pharmaceuticals through: Ex-U.S. licensing collaboration Generic patent litigation and patent prosecution Advanced developm

  12. Slide 12: Company focused on key business areas

    Company focused on 3 key business areas: 1. Opana ® ER treatment for chronic, moderate-to-severe pain Marketed in U.S. by Endo (launched in 2006) Generating a significant royalty to Penwest ($7.2 million in Q1 2010) Partnered with Valeant Pharmaceuticals for Canada, Australia, New Zealand 2. A0001 b

  13. Slide 13: 2010 Business Plan

    2010 Business Plan Working closely with Endo to maximize the value of Opana ® ER Completing both Phase IIa trials of A0001, analyzing the data and making a “go/no -go” decision Exploring potential licensing opportunities for A0001 in anticipation of the completion of the Phase IIa trials Growing our

  14. Slide 14: Opana ER Overview

    Opana ® ER Overview Developed using TIMERx ® Penwest s technology Marketed by Endo Pharmaceuticals Indication: For the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time Opana ® ER 2008 2009 Q1 2010 Endo s net sales $1

  15. Slide 15: Opana ER TRx Demand Continuing Strong Growth Trend

    Opana ® ER TRx Demand Continuing Strong Growth Trend TRx Opana ® ER Quarterly TRx Volume 180,000 160,000 140,000 120,000 100,000 80,000 4Q 08 1Q 09 2Q 09 3Q 09 4Q 09 1Q 10 ‘10 15

  16. Slide 16: Opana ER Financials U.S.

    Opana ® ER Financials U.S. Penwest receives tiered royalty based on annual U.S. net sales of Opana ® ER 22% up to $150m in sales 25%+ increasing in regular increments with net sales Top rate of 30% on sales Recorded $7.2m of royalty revenue for Agreed to repay $28M in unfunded development costs thro

  17. Slide 17: Opana ER Outside U.S.

    Opana ® ER Outside U.S. Worldwide rights ex-U.S. jointly owned with Endo Economics to be shared 50/50 In June 09, announced Valeant for Canada, Australia and New deal with Zealand Seeking collaborations in Europe, South America and Asia 17

  18. Slide 18: Opana ER Patent Status

    Opana ® ER Patent Status Multiple generic filers in the U.S. Original filers: IMPAX, Actavis, Sandoz, Barr Recent filers: Watson, Roxanne (running 2 1 / 2 years behind) Penwest and Endo have sued all generic filers Settled with Actavis in 2009 and Barr/Teva in Q1 10 Impax recently received tentative

  19. Slide 19: A0001

    A0001: átocopherolquinone O HO C CH 3 H 3 CH 3 CH 3 H 3C CH 3 H 3C CH 3 O Coenzyme Q class of drugs, with improved bioavailability Marketed in the 70 s in France for Preclinical assays suggest strong potency and Phase I demonstrated good drug pharmacokinetics Targeting development in two mitochondri

  20. Slide 20: A0001: Friedreich's Ataxia

    A0001: Friedreich’s Currently no approved therapies in U.S. or Europe Severe genetic disorder Degeneration of nerve and muscle tissue, loss of muscle control Impaired movements, muscle wasting Thickening of heart walls (cardiomyopathy) Caused by reduced level of fraxtaxin (key protein in mitochondri

  21. Slide 21: Phase IIa Friedreich's

    Phase IIa Friedreich’s n=30 Patients 14 Days 28 Days High Dose A0001 Moderate Dose Placebo Control Single site Children s Hospital of Double blind, randomized, placebo-controlled parallel group study Initiated trial in December 2009; expect to complete trial by end of Endpoints: Primary Change in Di

  22. Slide 22: A0001: MELAS Syndrome

    A0001: MELAS Syndrome Currently no approved therapies in U.S. or Europe Rare, progressive, genetic neurodegenerative disorder Involves multiple system organs including CNS, skeletal, muscle, eye and cardiac muscle Presentation typically occurs with stroke-like symptom Onset typically 4-15 years of a

  23. Slide 23: Phase IIa MELAS

    Phase IIa “MELAS” n=21 Patients 14 Days 28 Days High Dose A0001 Placebo Control Single site, Newcastle, UK Double blind, randomized, placebo-controlled parallel group study Initiated February 10. by end of Q3 10 Expect to Endpoints: Primary — metabolic imaging, functional assessments, and a number o

  24. Slide 24: A0001: Development To Date & Plan

    A0001: Development To Date & Plan Safety Completed Phase I safety program Completed 6-month preclinical tox program Established initial safety in animals and healthy volunteers Phase IIa Initiated Phase IIa trials in Expect to complete studies by end In parallel with development, we will be explorin

  25. Slide 25: Drug Delivery Technologies

    Drug Delivery Technologies Our oral controlled release technologies can be customized to deliver drugs via a wide range of desired release profiles Valuable technology successfully used with Opana ® ER Oral controlled release technology based on Dual-delivery system a natural gum matrix. which can r

  26. Slide 26: Drug Delivery Technology Licensing

    Drug Delivery Technology Licensing Pursuing technology licensing collaborations with companies utilizing our extended release technologies and formulation expertise. Typical deal consists of: Growing Revenues: Signing fee $2.5M Reimbursement of our development costs Revenue covers costs of R&D salar

  27. Slide 27: Current Drug Delivery Collaborations

    Current Drug Delivery Collaborations Signed 4 collaborations using TIMERx ® for lifecycle management of marketed products Signed 2 deals in 2009 October 2009 announced successful proof of principal in Phase I study of formulation under first Otsuka deal Several formulations currently in ongoing clin

  28. Slide 28: Cost Cutting Efforts and Financial Overview

    Cost Cutting Efforts and Financial Overview

  29. Slide 29: Details of Cost Cutting Effort

    Details of Cost Cutting Effort Reduced headcount from 76 to 38 employees, or 50%, as we have focused the business plan Consolidated two office locations into one Narrowed the R&D portfolio to most promising opportunity in A0001 Drug delivery collaborations provide reimbursement of R&D salaries and f

  30. Slide 30: Financially Solid: 2010 Guidance

    Financially Solid 2010 Guidance 2008 2009 2010% Actual Actual Guidance Change Revenues $9m $24m $43-$45m 83% S,G &A $12m $9m $6.5-$7.5m (22)% R&D $21m $12m $10.5-$11.5m (8)% Net Loss $(27)m $ (1.5)m Profitable Weighted avg shares o/s 31.9m Improvement in revenues being driven by increased revenues f

  31. Slide 31: Balance Sheet

    Balance Sheet March 31, 2010 Cash $11.5m Line of Credit to be repaid by Sept 2010 $2.7m No capital required to execute business plan in 2010 Board announced intent to authorize a special cash dividend of $0.50 — $0.75/share in Q4 10 credit

  32. Slide 32: Board Focus on Shareholder Value

    Board Focus on Shareholder Value 2007 Focused effort to bring on new Board members; 50% of 2009 Board is new Jan. 2009 Announced focused business plan in response to challenging economic conditions and shareholder concerns Jan.-Dec. 2009 Significantly reduced headcount and expenses to support more f

  33. Slide 33: This is Not an Entrenched Board

    This is Not an Entrenched Board 2004 2005 2006 2007 2008 2009 Hamachek Henel Henel Hennessey Hennessey Freiman Goyan Hennessey Hennessey Staniforth Staniforth VanLent Henel Staniforth Staniforth Freiman Freiman Drake Hennessey Freiman Freiman VanLent VanLent Good Staniforth VanLent VanLent Drake Dra

  34. Slide 34: Strong Balanced Working Board

    Strong Balanced Working Board Directors have diverse skills including various functional expertise from the industry as well as representation Board members are independent of each other Checks and balances exist Represents the perspectives of all shareholders Since Tang and Edelman joined the Board

  35. Slide 35: 2010 Nominating & Governance Committee Conclusions

    2010 Nominating & Governance Committee Conclusions

  36. Slide 36: 2010 Nomination Process

    2010 Nomination Process N&G Committee: Anne VanLent, Chair David Meeker Peter Drake 3 directors independent of this Tang and Edelman nominated 3 individuals for consideration Conducted thorough and fair review of each candidate Interviewed 2 of 3 candidates in person Offered compromise proposals Tan

  37. Slide 37: Comparison of Candidates

    Comparison of Candidates Tang Candidates: Board Nominees: John Lemkey Paul E. Freiman CFO at Tang Capital Current Chairman of the Board No operating experience Veteran of the industry Financial background (skills represented on Board) Former Chairman and CEO of Syntex No public company board experie

  38. Slide 38: Nominating & Governance Committee Recommendations

    Nominating & Governance Committee Recommendations Committee recommended Board slate of Paul Freiman, Jennifer Good and Christophe Bianchi Recommendation based on: Concern regarding the independence of the Tang and Edelman slate Board nominees had more expertise and experience

  39. Slide 39: Conclusions

    Conclusions

  40. Slide 40: Disappointing to be here again a year later

    Disappointing to be here again a year later We achieved our goals for 2009 track record of execution Stock price has risen significantly Executing on a plan that is similar to the plan they are now proposing Critical decisions/actions upcoming Need right team making these decisions and taking action

  41. Slide 41: Disruptive to the Company

    Disruptive to the Company Proxy contest has been very costly for the Company and its shareholders Difficult on existing partnerships and negotiations of new collaborations Disruptive to morale of employees who are focused on executing against our plan

  42. Slide 42: Tang and Edelman want Control!

    Tang and Edelman want Control! Tang and Edelman nominees less qualified; less likely to represent the interests of all shareholders Tang and Edelman have no alternative plan Risk of disrupting execution of focused plan that is working — proxy suggestion of management change and employee downsizing

  43. Slide 43: Penwest

    AaFenwest (Nasdaq: PPCO) June 2010 saPenwest

Penwest Pharmaceuticals — Proxy Contest (June 2010) on 6ix